American association of Clinical Endocrinologists, American college of endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules - 2016 update

Endocrine Practice

Volumn 22, Issue , 2016, Pages

  Gharib, Hossein ^a   Papini, Enrico ^b   Garber, Jeffrey R ^c,d   Duick, Daniel S ^e   Harrell, R Mack ^f   Hegedüs, Laszlo ^g   Paschke, Ralf ^h   Valcavi, Roberto ⁱ   Vitti, Paolo ^j   Balafouta, Sofia Tseleni ^k   Baloch, Zubair ^k   Crescenzi, Anna ^k   Dralle, Henning ^k   Frasoldati, Andrea ^k   Gärtner, Roland ^k   Guglielmi, Rinaldo ^k   Mechanick, Jeffrey I ^k   Reiners, Christoph ^k   Szabolcs, Istvan ^k   Zeiger, Martha A ^k   Zini, Michele ^k   more..

^a Mayo Clinic College of Medicine   (United States)

^b REGINA APOSTOLORUM HOSPITAL   (Italy)

^c HARVARD VANGUARD MEDICAL ASSOCIATES   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^f Memorial Center for Integrative Endocrine Surgery   (United States)

^g UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^h UNIVERSITY OF CALGARY   (Canada)

ⁱ Endocrinology Unit   (Italy)

^j UNIVERSITY OF PISA   (Italy)

^k NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANTITHYROID AGENT; CALCITONIN; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; LEVOTHYROXINE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PARATHYROID HORMONE; RADIOACTIVE IODINE; SODIUM IODIDE I 131; THYROGLOBULIN; THYROID HORMONE;

ABLATION THERAPY; BIBLIOGRAPHIC DATABASE; CALCIFICATION; CLINICAL DECISION MAKING; CLINICAL EVALUATION; CLINICAL PRACTICE; COCHRANE LIBRARY; COMPUTER ASSISTED TOMOGRAPHY; CYTOCHEMISTRY; CYTODIAGNOSIS; CYTOPATHOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIATED THYROID CANCER; ECHOGRAPHY; ELASTOGRAPHY; EMBASE; ENDOCRINE SURGERY; ENDOCRINOLOGIST; EVIDENCE BASED PRACTICE; FINE NEEDLE ASPIRATION BIOPSY; FOLLOW UP; FROZEN SECTION; GENETIC MARKER; HEALTH CARE ORGANIZATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOCYTOCHEMISTRY; INTERMEDIATE RISK PATIENT; LABORATORY TEST; LARGE CORE NEEDLE BIOPSY; LASER SURGERY; LOW RISK PATIENT; LYMPH NODE; MEDICAL DECISION MAKING; MEDICAL EXPERT; MEDICAL HISTORY; MEDLINE; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOCYTOMA; PATHOLOGIST; PATIENT INFORMATION; PATIENT PARTICIPATION; PATIENT PREFERENCE; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREDICTIVE VALUE; PREGNANCY; PREOPERATIVE EVALUATION; RADIOFREQUENCY ABLATION; RADIOISOTOPE THERAPY; RATING SCALE; REVIEW; RISK FACTOR; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SUBTOTAL THYROIDECTOMY; SURGEON; SYSTEMATIC REVIEW; THYROID CANCER; THYROID DISEASE; THYROID FOLLICULAR CARCINOMA; THYROID GLAND; THYROID INCIDENTALOMA; THYROID MEDULLARY CARCINOMA; THYROID NODULE; THYROID PAPILLARY CARCINOMA; THYROID SCINTISCANNING; TUMOR VOLUME; CLASSIFICATION; DIAGNOSTIC IMAGING; ENDOCRINE SYSTEM EXAMINATION; ENDOCRINOLOGY; FEMALE; ITALY; ORGANIZATION AND MANAGEMENT; PATHOLOGY; PROCEDURES; STANDARDS; UNITED STATES;

BIOPSY, FINE-NEEDLE; DIAGNOSTIC IMAGING; DIAGNOSTIC TECHNIQUES, ENDOCRINE; ENDOCRINOLOGY; FEMALE; HUMANS; ITALY; PREGNANCY; THYROID NODULE; UNITED STATES;

EID: 84982283721     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP161208.GL     Document Type: Review

References (376)

1. Gharib H, Papini E. Thyroid nodules: clinical importance, assessment, and treatment. Endocrinol Metab Clin North Am. 2007;36:707-735, vi. [EL 4-review]
2. Hegedüs L. Clinical practice. The thyroid nodule. N Engl J Med. 2004;351:1764-1771. [EL 4-review]
3. Tunbridge WM, Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clin Endocrinol (Oxf). 1977;7:481-493. [EL 2]
4. Reiners C, Wegscheider K, Schicha H, et al. Prevalence of thyroid disorders in the working population of Germany: ultrasonography screening in 96,278 unselected employees. Thyroid. 2004;14:926-932. [EL 2]
5. Dean DS, Gharib H. Epidemiology of thyroid nodules. Best Pract Res Clin Endocrinol Metab. 2008;22:901-911. [EL 4]
6. Guth S, Theune U, Aberle J, Galach A, Bamberger CM. Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination. Eur J Clin Invest. 2009;39:699-706. [EL 2]
7. Mortensen JD, Woolner LB, Bennett WA. Gross and microscopic findings in clinically normal thyroid glands. J Clin Endocrinol Metab. 1955;15:1270-1280. [EL 3]
8. Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med. 1997;126:226-231. [EL 4]
9. Steele SR, Martin MJ, Mullenix PS, Azarow KS, Andersen CA. The significance of incidental thyroid abnormalities identified during carotid duplex ultrasonography. Arch Surg. 2005;140:981-985. [EL 2]
10. Kang BJ, O JH, Baik JH, Jung SL, Park YH, Chung SK. Incidental thyroid uptake on F-18 FDG PET/CT: correlation with ultrasonography and pathology. Ann Nucl Med. 2009;23:729-737. [EL 2]
11. Jin J, McHenry CR. Thyroid incidentaloma. Best Pract Res Clin Endocrinol Metab. 2012;26:83-96. [EL 4]
12. Leenhardt L, Grosclaude P, Cherie-Challine L; Thyroid Cancer Committee. Increased incidence of thyroid carcinoma in France: a true epidemic or thyroid nodule management effects? Report from the French Thyroid Cancer Committee. Thyroid. 2004;14:1056-1060. [EL 4]
13. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295:2164-2167. [EL 2]
14. Zevallos JP, Hartman CM, Kramer JR, Sturgis EM, Chiao EY. Increased thyroid cancer incidence corresponds to increased use of thyroid ultrasound and fine-needle aspiration: a study of the Veterans Affairs health care system. Cancer. 2015;121:741-746. [EL 3]
15. Ito Y, Uruno T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid. 2003;13:381-387. [EL 3]
16. Cronan JJ. Thyroid nodules: is it time to turn off the US machines? Radiology. 2008;247:602-604. [EL 4]
17. Howlett DC, Speirs A. The thyroid incidentaloma: ignore or investigate? J Ultrasound Med. 2007;26:1367-1371. [EL 4]
18. Rosenbaum MA, McHenry CR. Contemporary management of papillary carcinoma of the thyroid gland. Expert Rev Anticancer Ther. 2009;9:317-329. [EL 4-review]
19. DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press, 2004. [EL 4-review]
20. Aghini-Lombardi F, Antonangeli L, Martino E, et al. The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. J Clin Endocrinol Metab. 1999;84:561-566. [EL 2]
21. Puñales MK, da Rocha AP, Meotti C, Gross JL, Maia AL. Clinical and oncological features of children and young adults with multiple endocrine neoplasia type 2A. Thyroid. 2008;18:1261-1268. [EL 2]
22. Campanella P, Ianni F, Rota CA, Corsello SM, Pontecorvi A. Quantification of cancer risk of each clinical and ultrasonographic suspicious feature of thyroid nodules: a systematic review and meta-analysis. Eur J Endocrinol. 2014;170:R203-R211. [EL 2]
23. Capezzone M, Marchisotta S, Cantara S, Busonero G, Brilli L, Pazaitou-Panayiotou K. Familial non-medullary thyroid carcinoma displays the features of clinical anticipation suggestive of a distinct biological entity. Endocr Relat Cancer. 2008;15:1075-1081. [EL 3]
24. Corrias A, Einaudi S, Chiorboli E, et al. Accuracy of fine needle aspiration biopsy of thyroid nodules in detecting malignancy in childhood: comparison with conventional clinical, laboratory, and imaging approaches. J Clin Endocrinol Metab. 2001;86:4644-4648. [EL 3]
25. Durante C, Costante G, Lucisano G, et al. The natural history of benign thyroid nodules. JAMA. 2015;313:926-935. [EL 2]
26. Negro R. What happens in a 5-year follow-up of benign thyroid nodules. J Thyroid Res. 2014;2014:459791. [EL 3]
27. Jarløv AE, Nygaard B, Hegedüs L, Hartling SG, Hansen JM. Observer variation in the clinical and laboratory evaluation of patients with thyroid dysfunction and goiter. Thyroid. 1998;8:393-398. [EL 3]
28. Gough J, Scott-Coombes D, Fausto Palazzo F. Thyroid incidentaloma: an evidence-based assessment of management strategy. World J Surg. 2008;32:1264-1268. [EL 4]
29. Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab. 2002;87:1941-1946. [EL 3]
30. Christensen SB, Bondeson L, Ericsson UB, Lindholm K. Prediction of malignancy in the solitary thyroid nodule by physical examination, thyroid scan, fine-needle biopsy and serum thyroglobulin: a prospective study of 100 surgically treated patients. Acta Chir Scand. 1984;150:433-439. [EL 3]
31. Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA. Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. J Clin Endocrinol Metab. 2006;91:4295-4301. [EL 3]
32. Gerschpacher M, Gobl C, Anderwald C, Gessl A, Krebs M. Thyrotropin serum concentrations in patients with papillary thyroid microcancers. Thyroid. 2010;20:389-392. [EL 3]
33. Fiore E, Vitti P. Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. J Clin Endocrinol Metab. 2012;97:1134-1145. [EL 2]
34. Giovanella L, Fasolini F, Suriano S, Mazzucchelli L. Hyperfunctioning solid/trabecular follicular carcinoma of the thyroid gland. J Oncol. 2010;2010. pii: 635984. [EL 3]
35. Ashcraft MW, Van Herle AJ. Management of thyroid nodules. II: Scanning techniques, thyroid suppressive therapy, and fine needle aspiration. Head Neck Surg. 1981;3:297-322. [EL 4-review]
36. Yano Y, Shibuya H, Kitagawa W, et al. Recent outcome of Graves' disease patients with papillary thyroid cancer. Eur J Endocrinol. 2007;157:325-329. [EL 3]
37. Shetty SK, Maher MM, Hahn PF, Halpern EF, Aquino SL. Significance of incidental thyroid lesions detected on CT: correlation among CT, sonography, and pathology. AJR Am J Roentgenol. 2006;187:1349-1356. Erratum in: AJR Am J Roentgenol. 2007;188:8. [EL 3]
38. Razek AA, Sadek AG, Kombar OR, Elmahdy TE, Nada N. Role of apparent diffusion coefficient values in differentiation between malignant and benign solitary thyroid nodules. AJNR Am J Neuroradiol. 2008;29:563-568. [EL 3]
39. Are C, Hsu JF, Schoder H, Shah JP, Larson SM, Shaha AR. FDG-PET detected thyroid incidentalomas: need for further investigation? Ann Surg Oncol. 2007;14:239-247. [EL 3]
40. Choi JY, Lee KS, Kim HJ, et al. Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization. J Nucl Med. 2006;47:609-615. [EL 3]
41. Soelberg KK, Bonnema SJ, Brix TH, Hegedüs L. Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review. Thyroid. 2012;22:918-925. [EL 2]
42. Hurtado-López LM, Arellano-Montaño S, Torres-Acosta EM, et al. Combined use of fine-needle aspiration biopsy, MIBI scans and frozen section biopsy offers the best diagnostic accuracy in the assessment of the hypofunctioning solitary thyroid nodule. Eur J Nucl Med Mol Imaging. 2004;31:1273-1279. [EL 3]
43. Baskin HJ. Ultrasound of thyroid nodules. In: Baskin HJ, ed. Thyroid Ultrasound and Ultrasound-Guided FNA Biopsy. Boston, MA: Springer U.S.; 2000: 71-86. [EL 4-review]
44. Solbiati L, Osti V, Cova L, Tonolini M. Ultrasound of thyroid, parathyroid glands and neck lymph nodes. Eur Radiol. 2001;11:2411-2424. [EL 4-review]
45. Ahuja A, Ying M. Sonography of neck lymph nodes. Part II: abnormal lymph nodes. Clin Radiol. 2003;58:359-366. [EL 4-review]
46. Frates MC, Benson CB, Doubilet PM, et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab. 2006;91:3411-3417. [EL 3]
47. Mandel SJ. Diagnostic use of ultrasonography in patients with nodular thyroid disease. Endocr Pract. 2004;10:246-252. [EL 4-review]
48. Horvath E, Majlis S, Rossi R, et al. An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab. 2009;94:1748-1751. [EL 2]
49. Moon WJ, Jung SL, Lee JH, et al. Benign and malignant thyroid nodules: US differentiation multicenter retrospective study. Radiology. 2008;247:762-770. [EL 3]
50. Kim EK, Park CS, Chung WY, et al. New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR Am J Roentgenol. 2002;178:687-691. [EL 2]
51. Cappelli C, Castellano M, Pirola I, et al. Thyroid nodule shape suggests malignancy. Eur J Endocrinol. 2006;155: 27-31. [EL 3]
52. Kwak JY, Jung I, Baek JH, et al. Image reporting and characterization system for ultrasound features of thyroid nodules: multicentric Korean retrospective study. Korean J Radiol. 2013;14:110-117. Erratum in: Korean J Radiol. 2013;14:389. [EL 2]
53. Hagag P, Strauss S, Weiss M. Role of ultrasound-guided fine-needle aspiration biopsy in evaluation of nonpalpable thyroid nodules. Thyroid. 1998;8:989-995. [EL 3]
54. Verburg FA, Mader U, Luster M, Reiners C. Primary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2009;71:291-297. [EL 3]
55. McHenry CR, Huh ES, Machekano RN. Is nodule size an independent predictor of thyroid malignancy? Surgery. 2008;144:1062-1068; discussion 1068-1069. [EL 3]
56. Papini E, Petrucci L, Guglielmi R, et al. Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. J Clin Endocrinol Metab. 1998;83:780-783. [EL 1]
57. Kuma K, Matsuzuka F, Yokozawa T, Miyauchi A, Sugawara M. Fate of untreated benign thyroid nodules: results of long-term follow-up. World J Surg. 1994;18: 495-498; discussion 499. [EL 2]
58. Alexander EK, Hurwitz S, Heering JP, et al. Natural history of benign solid and cystic thyroid nodules. Ann Intern Med. 2003;138:315-318. [EL 3]
59. Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients. World J Surg. 2010;34:28-35. [EL 2]
60. Gharib H, Papini E, Paschke R, et al. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. J Endocrinol Invest. 2010;33 5 Suppl:1-50. [EL 4]
61. Perros P, Boelaert K, Colley S, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol (Oxf). 2014;81 Suppl 1:1-122. [EL 4]
62. Frates MC, Benson CB, Charboneau JW, et al. Management of thyroid nodules detected at US: Society of Radiologists in ultrasound consensus conference statement. Radiology. 2005;237:794-800. [EL 4]
63. Brauer VF, Eder P, Miehle K, Wiesner TD, Hasenclever H, Paschke R. Interobserver variation for ultrasound determination of thyroid nodule volumes. Thyroid. 2005;15:1169-1175. [EL 2]
64. Gallo M, Pesenti M, Valcavi R. Ultrasound thyroid nodule measurements: the "gold standard" and its limitations in clinical decision making. Endocr Pract. 2003;9:194-199. [EL 4-review]
65. Schlogl S, Werner E, Lassmann M, et al. The use of three-dimensional ultrasound for thyroid volumetry. Thyroid. 2001;11:569-574. [EL 3]
66. Kollorz EK, Hahn DA, Linke R, Goecke TW, Hornegger J, Kuwert T. Quantification of thyroid volume using 3-D ultrasound imaging. IEEE Trans Med Imaging. 2008;27:457-466. [EL 3]
67. Kim EK, Park CS, Chung WY, et al. New sonographic criteria for recommending fine-needle aspiration biopsy of nonpalpable solid nodules of the thyroid. AJR Am J Roentgenol. 2002;178:687-691. [EL 2]
68. Wienke JR, Chong WK, Fielding JR, Zou KH, Mittelstaedt CA. Sonographic features of benign thyroid nodules: interobserver reliability and overlap with malignancy. J Ultrasound Med. 2003;22:1027-1031. [EL 2]
69. Choi SH, Kim EK, Kwak JY, Kim MJ, Son EJ. Interobserver and intraobserver variations in ultrasound assessment of thyroid nodules. Thyroid. 2010;20:167-172. [EL 2]
70. Lee MJ, Kim EK, Kwak JY, Kim MJ. Partially cystic thyroid nodules on ultrasound: probability of malignancy and sonographic differentiation. Thyroid. 2009;19:341-346. [EL 3]
71. Chan BK, Desser TS, McDougall IR, Weigel RJ, Jeffrey RB Jr. Common and uncommon sonographic features of papillary thyroid carcinoma. J Ultrasound Med. 2003;22:1083-1090. [EL 2]
72. Lee S, Shin JH, Han BK, Ko EY. Medullary thyroid carcinoma: comparison with papillary thyroid carcinoma and application of current sonographic criteria. AJR Am J Roentgenol. 2010;194:1090-1094. [EL 3]
73. Kim SH, Kim BS, Jung SL, et al. Ultrasonographic findings of medullary thyroid carcinoma: a comparison with papillary thyroid carcinoma. Korean J Radiol. 2009;10:101-105. [EL 3]
74. Reading CC, Charboneau JW, Hay ID, Sebo TJ. Sonography of thyroid nodules: a "classic pattern" diagnostic approach. Ultrasound Q. 2005;21:157-165. [EL 4]
75. Yuan WH, Chiou HJ, Chou YH, et al. Gray-scale and color Doppler ultrasonographic manifestations of papillary thyroid carcinoma: analysis of 51 cases. Clin Imaging. 2006;30:394-401. [EL 3]
76. Propper RA, Skolnick ML, Weinstein BJ, Dekker A. The nonspecificity of the thyroid halo sign. J Clin Ultrasound. 1980;8:129-132. [EL 3]
77. Moon WJ, Baek JH, Jung SL, et al. Ultrasonography and the ultrasound-based management of thyroid nodules: consensus statement and recommendations. Korean J Radiol. 2011;12:1-14. [EL 4]
78. Khoo ML, Asa SL, Witterick IJ, Freeman JL. Thyroid calcification and its association with thyroid carcinoma. Head Neck. 2002;24:651-655. [EL 3]
79. Taki S, Terahata S, Yamashita R, et al. Thyroid calcifications: sonographic patterns and incidence of cancer. Clin Imaging. 2004;28:368-371. [EL 3]
80. Chammas MC, de Araujo Filho VJ, Moysés RA, et al. Predictive value for malignancy in the finding of microcalcifications on ultrasonography of thyroid nodules. Head Neck. 2008;30:1206-1210. [EL 2]
81. Kim MJ, Kim EK, Park SI, et al. US-guided fine-needle aspiration of thyroid nodules: indications, techniques, results. Radiographics. 2008;28:1869-1886; discussion 1887. [EL 4]
82. Wang N, Xu Y, Ge C, Guo R, Guo K. Association of sonographically detected calcification with thyroid carcinoma. Head Neck. 2006;28:1077-1083. [EL 3]
83. Hong YJ, Son EJ, Kim EK, Kwak JY, Hong SW, Chang HS. Positive predictive values of sonographic features of solid thyroid nodule. Clin Imaging. 2010;34:127-33. [EL 2]
84. Wu CW, Dionigi G, Lee KW, et al. Calcifications in thyroid nodules identified on preoperative computed tomography: patterns and clinical significance. Surgery. 2012;151:464-470. [EL 3]
85. Guglielmi R, Pacella CM, Bianchini A, et al. Percutaneous ethanol injection treatment in benign thyroid lesions: role and efficacy. Thyroid. 2004;14:125-131. [EL 2]
86. Yoon DY, Lee JW, Chang SK, et al. Peripheral calcification in thyroid nodules: ultrasonographic features and prediction of malignancy. J Ultrasound Med. 2007;26:1349-1355; quiz 1356-1357. [EL 2]
87. Kim BM, Kim MJ, Kim EK, et al. Sonographic differentiation of thyroid nodules with eggshell calcifications. J Ultrasound Med. 2008;27:1425-1430. [EL 2]
88. Tamsel S, Demirpolat G, Erdogan M, et al. Power Doppler US patterns of vascularity and spectral Doppler US parameters in predicting malignancy in thyroid nodules. Clin Radiol. 2007;62:245-251. [EL 2]
89. Moon HJ, Kwak JY, Kim MJ, Son EJ, Kim EK. Can vascularity at power Doppler US help predict thyroid malignancy? Radiology. 2010;255:260-269. [EL 2]
90. Jun P, Chow LC, Jeffrey RB. The sonographic features of papillary thyroid carcinomas: pictorial essay. Ultrasound Q. 2005;21:39-45. [EL 4]
91. Yoon JH, Kim EK, Hong SW, Kwak JY, Kim MJ. Sonographic features of the follicular variant of papillary thyroid carcinoma. J Ultrasound Med. 2008;27:1431-1437. [EL 2]
92. Kim DS, Kim JH, Na DG, et al. Sonographic features of follicular variant papillary thyroid carcinomas in comparison with conventional papillary thyroid carcinomas. J Ultrasound Med. 2009;28:1685-1692. [EL 2]
93. Choi YJ, Shin JH, Kim JH, Jung SL, Son EJ, Oh YL. Tall cell variant of papillary thyroid carcinoma: sonographic and clinical findings. J Ultrasound Med. 2011;30: 853-858. [EL 2]
94. Zhang Y, Xia D, Lin P, Gao L, Li G, Zhang W. Sonographic findings of the diffuse sclerosing variant of papillary carcinoma of the thyroid. J Ultrasound Med. 2010;29:1223-1226. [EL 3]
95. Lee JY, Shin JH, Han BK, et al. Diffuse sclerosing variant of papillary carcinoma of the thyroid: imaging and cytologic findings. Thyroid. 2007;17:567-573. [EL 3]
96. Kwak JY, Kim EK, Hong SW, et al. Diffuse sclerosing variant of papillary carcinoma of the thyroid: ultrasound features with histopathological correlation. Clin Radiol. 2007;62:382-386. [EL 3]
97. Jeh SK, Jung SL, Kim BS, Lee YS. Evaluating the degree of conformity of papillary carcinoma and follicular carcinoma to the reported ultrasonographic findings of malignant thyroid tumor. Korean J Radiol. 2007;8:192-197. [EL 2]
98. Kobayashi K, Fukata S, Miyauchi A. Diagnosis of follicular carcinoma of the thyroid: role of sonography in preoperative diagnosis of follicular nodules. J Med Ultrasonics. 2005;32:153-158. [EL 2]
99. Sillery JC, Reading CC, Charboneau JW, Henrichsen TL, Hay ID, Mandrekar JN. Thyroid follicular carcinoma: sonographic features of 50 cases. AJR Am J Roentgenol. 2010;194:44-54. [EL 2]
100. Gulcelik NE, Gulcelik MA, Kuru B. Risk of malignancy in patients with follicular neoplasm: predictive value of clinical and ultrasonographic features. Arch Otolaryngol Head Neck Surg. 2008;134:1312-1315. [EL 2]
101. Fukunari N, Nagahama M, Sugino K, Mimura T, Ito K, Ito K. Clinical evaluation of color Doppler imaging for the differential diagnosis of thyroid follicular lesions. World J Surg. 2004;28:1261-1265. [EL 2]
102. Shin JH, Han BK, Ko EY, Oh YL, Kim JH. Differentiation of widely invasive and minimally invasive follicular thyroid carcinoma with sonography. Eur J Radiol. 2010;74:453-457. [EL 2]
103. Maizlin ZV, Wiseman SM, Vora P, et al. Hurthle cell neoplasms of the thyroid: sonographic appearance and histologic characteristics. J Ultrasound Med. 2008;27:751-757; quiz 759. [EL 3]
104. Lee SK, Rho BH, Woo SK. Hürthle cell neoplasm: correlation of gray-scale and power Doppler sonographic findings with gross pathology. J Clin Ultrasound. 2010;38: 169-176. [EL 2]
105. Choi N, Moon WJ, Lee JH, Baek JH, Kim DW, Park SW. Ultrasonographic findings of medullary thyroid cancer: differences according to tumor size and correlation with fine needle aspiration results. Acta Radiol. 2011;52:312-316. [EL 3]
106. Trimboli P, Giovanella L, Crescenzi A, et al. Medullary thyroid cancer diagnosis: an appraisal. Head Neck. 2014;36:1216-1223. [EL 4]
107. Rago T, Santini F, Scutari M, Pinchera A, Vitti P. Elastography: new developments in ultrasound for predicting malignancy in thyroid nodules. J Clin Endocrinol Metab. 2007;92:2917-2922. [EL 3]
108. Azizi G, Keller J, Lewis M, Puett D, Rivenbark K, Malchoff C. Performance of elastography for the evaluation of thyroid nodules: a prospective study. Thyroid. 2013;23:734-740. [EL 3]
109. Trimboli P, Guglielmi R, Monti S, et al. Ultrasound sensitivity for thyroid malignancy is increased by real-time elastography: a prospective multicenter study. J Clin Endocrinol Metab. 2012;97:4524-4530. [EL 2]
110. Ghajarzadeh M, Sodagari F, Shakiba M. Diagnostic accuracy of sonoelastography in detecting malignant thyroid nodules: a systematic review and meta-analysis. AJR Am J Roentgenol. 2014;202:W379-W389. [EL 2]
111. Russ G, Royer B, Bigorgne C, Rouxel A, Bienvenu-Perrard M, Leenhardt L. Prospective evaluation of thyroid imaging reporting and data system on 4550 nodules with and without elastography. Eur J Endocrinol. 2013; 168:649-655. [EL 2]
112. Zhang YF, Liu C, Xu HX, et al. Acoustic radiation force impulse imaging: a new tool for the diagnosis of papillary thyroid microcarcinoma. Biomed Res Int. 2014;2014:416969. [EL 2]
113. Park AY, Son EJ, Han K, Youk JH, Kim JA, Park CS. Shear wave elastography of thyroid nodules for the prediction of malignancy in a large scale study. Eur J Radiol. 2015;84:407-412. [EL 2]
114. Liu BJ, Xu HX, Zhang YF, et al. Acoustic radiation force impulse elastography for differentiation of benign and malignant thyroid nodules with concurrent Hashimoto's thyroiditis. Med Oncol. 2015;32:50. [EL 3]
115. Rago T, Scutari M, Santini F, et al. Real-time elastosonography: useful tool for refining the presurgical diagnosis in thyroid nodules with indeterminate or nondiagnostic cytology. J Clin Endocrinol Metab. 2010;95:5274-5280. [EL 2]
116. Leenhardt L, Erdogan MF, Hegedüs L, et al. 2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer. Eur Thyroid J. 2013;2:147-159. [EL 4]
117. Lepoutre-Lussey C, Maddah D, Golmard JL, et al. Post-operative neck ultrasound and risk stratification in differentiated thyroid cancer patients with initial lymph node involvement. Eur J Endocrinol. 2014;170:837-846. [EL 2]
118. Leenhardt L, Hejblum G, Franc B, et al. Indications and limits of ultrasound-guided cytology in the management of nonpalpable thyroid nodules. J Clin Endocrinol Metab. 1999;84:24-28. [EL 2]
119. Pacini F, Fugazzola L, Lippi F, et al. Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. J Clin Endocrinol Metab. 1992;74:1401-1404. [EL 2]
120. Frasoldati A, Toschi E, Zini M, et al. Role of thyroglobulin measurement in fine-needle aspiration biopsies of cervical lymph nodes in patients with differentiated thyroid cancer. Thyroid. 1999;9:105-111. [EL 2]
121. Kamaya A, Tahvildari AM, Patel B, Willman JK, Jeffrey B, Desser T. Sonographic detection of extracapsular extension in papillary thyroid cancer. JUM. 2015;34:2225-2230. [EL 3]
122. Moon SJ, Kim DW, Kim SJ, Ha TK, Park HK, Jung SJ. Ultrasound assessment of degrees of extrathyroidal extension in papillary thyroid microcarcinoma. Endocr Pract. 2014;20:1037-1043. [EL 3]
123. Roti E, degli Uberti EC, Bondanelli M, Braverman LE. Thyroid papillary microcarcinoma: a descriptive and meta-analysis study. Eur J Endocrinol. 2008;159:659-673. [EL 4-review]
124. Verburg FA, Mader U, Luster M, Reiners C. Primary tumour diameter as a risk factor for advanced disease features of differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2009;71:291-297. [EL 3]
125. Mandel SJ. Diagnostic use of ultrasonography in patients with nodular thyroid disease. Endocr Pract. 2004;10:246-252. [EL 4-review]
126. Ahn SS, Kim EK, Kang DR, Lim SK, Kwak JY, Kim MJ. Biopsy of thyroid nodules: comparison of three sets of guidelines. AJR Am J Roentgenol. 2010;194:31-37. [EL 2]
127. D'Orsi CJ, Sickles EA, Mendelson EB, Morris EA, et al. ACR BI-RADS® Atlas, Breast Imaging Reporting and Data System. 4th ed. Reston, VA: American College of Radiology; 2003. [EL 4]
128. Horvath E, Majlis S, Rossi R, et al. An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab. 2009;94:1748-1751. [EL 2]
129. Kim DW, Park JS, In HS, Choo HJ, Ryu JH, Jung SJ. Ultrasound-based diagnostic classification for solid and partially cystic thyroid nodules. AJNR Am J Neuroradiol. 2012;33:1144-1149. [EL 2]
130. Lee YH, Kim DW, In HS, et al. Differentiation between benign and malignant solid thyroid nodules using an US classification system. Korean J Radiol. 2011;12:559-567. [EL 2]
131. Kwak JY, Han KH, Yoon JH, et al. Thyroid imaging reporting and data system for US features of nodules: a step in establishing better stratification of cancer risk. Radiology. 2011;260:892-899. [EL 2]
132. Russ G, Bigorgne C, Royer B, Rouxel A, Bienvenu-Perrard M. The Thyroid Imaging Reporting and Data System (TIRADS) for ultrasound of the thyroid [in French]. J Radiol. 2011;92:701-713. [EL 3]
133. Cosgrove D. Future prospects for SonoVue and CPS. Eur Radiol. 2004;14 Suppl 8:P116-P124. [EL 4]
134. Jiang J, Huang L, Zhang H, et al. Contrast-enhanced sonography of thyroid nodules. J Clin Ultrasound. 2015;43:153-156. [EL 2]
135. Ma JJ, Ding H, Xu BH, et al. Diagnostic performances of various gray-scale, color Doppler, and contrast-enhanced ultrasonography findings in predicting malignant thyroid nodules. Thyroid. 2014;24:355-363. [EL 3]
136. Papini E, Bizzarri G, Pacella CM. Percutaneous laser ablation of benign and malignant thyroid nodules. Curr Opin Endocrinol Diabetes Obes. 2008;15:434-439. [EL 4-review]
137. Weber AL, Randolph G, Aksoy FG. The thyroid and parathyroid glands: CT and MR imaging and correlation with pathology and clinical findings. Radiol Clin North Am. 2000;38:1105-1129. [EL 4-review]
138. Lee SY, Rhee CM, Leung AM, Braverman LE, Brent GA, Pearce EN. A review: radiographic iodinated contrast media-induced thyroid dysfunction. J Clin Endocrinol Metab. 2015;100:376-383. [EL 4]
139. de Groot JW, Links TP, Plukker JT, Lips CJ, Hofstra RM. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev. 2006;27:535-560. [EL 4]
140. Giovanella L, Ceriani L, Treglia G. Role of isotope scan, including positron emission tomography/computed tomography, in nodular goitre. Best Pract Res Clin Endocrinol Metab. 2014;28:507-518. [EL 4]
141. Rago T, Scutari M, Latrofa F, et al. The large majority of 1520 patients with indeterminate thyroid nodule at cytology have a favorable outcome, and a clinical risk score has a high negative predictive value for a more cumbersome cancer disease. J Clin Endocrinol Metab. 2014;99:3700-3707. [EL 2]
142. Nikivorov YE, Carty SE, Chiosea SI, et al. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer. 2014;120:3627-3634. [EL 2]
143. Ali SZ, Cibas ES, eds. The Bethesda System for Reporting Thyroid Cytopathology: Definitions, Criteria and Explanatory Notes. New York, NY: Springer; 2010. [EL 4]
144. Hor T, Lahiri SW. Bilateral thyroid hematomas after fine-needle aspiration causing acute airway obstruction. Thyroid. 2008;18:567-569. [EL 3]
145. Lee YH, Baek JH, Jung SL, et al. Ultrasound-guided fine needle aspiration of thyroid nodules: a consensus statement by the Korean Society of Thyroid Radiology. Korean J Radiol. 2015;16:391-401. [EL 4]
146. Abu-Yousef MM, Larson JH, Kuehn DM, Wu AS, Laroia AT. Safety of ultrasound-guided fine needle aspiration biopsy of neck lesions in patients taking antithrombotic/anticoagulant medications. Ultrasound Q. 2011;27: 157-159. [EL 2]
147. Wu HH, Jones JN, Osman J. Fine-needle aspiration cytology of the thyroid: ten years experience in a community teaching hospital. Diagn Cytopathol. 2006;34:93-96. [EL 3]
148. Danese D, Sciacchitano S, Farsetti A, Andreoli M, Pontecorvi A. Diagnostic accuracy of conventional versus sonography-guided fine-needle aspiration biopsy of thyroid nodules. Thyroid. 1998;8:15-21. [EL 4]
149. Deandrea M, Mormile A, Veglio M, et al. Fine-needle aspiration biopsy of the thyroid: comparison between thyroid palpation and ultrasonography. Endocr Pract. 2002; 8:282-286. [EL 3]
150. Can AS, Peker K. Comparison of palpation-versus ultrasound-guided fine-needle aspiration biopsies in the evaluation of thyroid nodules. BMC Res Notes. 2008;1:12. [EL 4]
151. Pitman MB, Abele J, Ali SZ, et al. Techniques for thyroid FNA: a synopsis of the National Cancer Institute thyroid fine-needle aspiration state of the science conference. Diagn Cytopathol. 2008;36:407-424. [EL 4]
152. Guidance on the reporting of thyroid cytology specimens [Internet]. London, UK: The Royal College of Pathologists; 2009. Available at: http://www.rcpath.org/Resources/RCPath/Migrated%20Resources/Documents/G/g089guidanceonthereportingofthyroidcytologyfinal.pdf, Accessed April 29, 2015 [EL 4]
153. Baloch ZW, LiVolsi VA, Asa SL, et al. Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute thyroid fine-needle aspiration state of the science conference. Diagn Cytopathol. 2008;36:425-437. [EL 4-consensus]
154. Nardi F, Basolo F, Crescenzi A, et al. Italian consensus for the classification and reporting of thyroid cytology. J Endocrinol Invest. 2014;37:593-599. [EL 4]
155. Moon JH, Kim YI, Lim JA, et al. Thyroglobulin in washout fluid from lymph node fine-needle aspiration biopsy in papillary thyroid cancer: large-scale validation of the cutoff value to determine malignancy and evaluation of discrepant results. J Clin Endocrinol Metab. 2013;98:1061-1068. [EL 3]
156. Bongiovanni M, Spitale A, Faquin WC, Mazzucchelli L, Baloch ZW. The Bethesda system for reporting thyroid cytopathology: a meta-analysis. Acta Cytol. 2012;56:333-339. [EL 2]
157. Cross PA, Poller D. The Bethesda thyroid terminology and progress towards international agreement on thyroid FNA cytology reporting. Cytopathology. 2010;21:71-74. [EL 4]
158. DeMay RM. Thyroid. In: The Art and Science of Cytopathology. Vol II. Chicago, IL: American Society of Clinical Pathologists; 1996: Chapter 17. [EL 4]
159. Kini SR. Specimen adequacy and assessment, reporting system. In: Thyroid Cytopathology: An Atlas and Text. Philadelphia, PA: Lippincott, Williams & Wilkins; 2008: 17-26. [EL 4]
160. Redman R, Zalaznick H, Mazzaferri EL, Massoll NA. The impact of assessing specimen adequacy and number of needle passes for fine-needle aspiration biopsy of thyroid nodules. Thyroid. 2006;16:55-60. [EL 3]
161. Piana S, Frasoldati A, Ferrari M, et al. Is a five-category reporting scheme for thyroid fine needle aspiration cytology accurate? Experience of over 18,000 FNAs reported at the same institution during 1998-2007. Cytopathology. 2011;22:164-173. [EL 3]
162. Bongiovanni M, Crippa S, Baloch Z, et al. Comparison of 5-tiered and 6-tiered diagnostic systems for the reporting of thyroid cytopathology: a multi-institutional study. Cancer Cytopathol. 2012;120:117-125. [EL 2]
163. Yang J, Schnadig V, Logrono R, Wasserman PG. Fine-needle aspiration of thyroid nodules: a study of 4703 patients with histologic and clinical correlations. Cancer. 2007;111:306-315. [EL 3]
164. Renshaw AA. Should "atypical follicular cells" in thyroid fine-needle aspirates be subclassified? Cancer Cytopathol. 2010;118:186-189. Erratum in: Cancer Cytopathol. 2010; 118:303. [EL 3]
165. VanderLaan PA, Marqusee E, Krane JF. Usefulness of diagnostic qualifiers for thyroid fine-needle aspirations with atypia of undetermined significance. Am J Clin Pathol. 2011;136:572-577. [EL 3]
166. Singh RS, Wang HH. Eliminating the "atypia of undetermined significance/follicular lesion of undetermined significance" category from the Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol. 2011;136: 896-902. [EL 4]
167. Kocjan G, Chandra A, Cross PA, et al. The interobserver reproducibility of thyroid fine-needle aspiration using the UK Royal College of Pathologists' classification system. Am J Clin Pathol. 2011;135:852-859. [EL 3]
168. Hamberger B, Gharib H, Melton LJ 3rd, Goellner JR, Zinsmeister AR. Fine-needle aspiration biopsy of thyroid nodules: impact on thyroid practice and cost of care. Am J Med. 1982;73:381-384. [EL 3]
169. Kwak JY, Kim EK, Kim HJ, Kim MJ, Son EJ, Moon HJ. How to combine ultrasound and cytological information in decision making about thyroid nodules. Eur Radiol. 2009;19:1923-1931. [EL 3]
170. Orlandi A, Puscar A, Capriata E, Fideleff H. Repeated fine-needle aspiration of the thyroid in benign nodular thyroid disease: critical evaluation of long-term follow-up. Thyroid. 2005;15:274-278. [EL 3]
171. Menéndez Torre E, Pineda Arribas J, Martìnez de Esteban JP, López Carballo MT, de Miguel C, Salvador P. Value of repeated fine needle aspiration cytology in patients with nodular goiter. Acta Cytol. 2007;51:850-852. [EL 3]
172. Frasoldati A, Toschi E, Zini M, et al. Role of thyroglobulin measurement in fine-needle aspiration biopsies of cervical lymph nodes in patients with differentiated thyroid cancer. Thyroid. 1999;9:105-111. [EL 3]
173. Pacini F, Fugazzola L, Lippi F, et al. Detection of thyroglobulin in fine needle aspirates of nonthyroidal neck masses: a clue to the diagnosis of metastatic differentiated thyroid cancer. J Clin Endocrinol Metab. 1992;74:1401-1404. [EL 3]
174. Uruno T, Miyauchi A, Shimizu K, et al. Usefulness of thyroglobulin measurement in fine-needle aspiration biopsy specimens for diagnosing cervical lymph node metastasis in patients with papillary thyroid cancer. World J Surg. 2005;29:483-485. [EL 3]
175. Baskin HJ. Detection of recurrent papillary thyroid carcinoma by thyroglobulin assessment in the needle washout after fine-needle aspiration of suspicious lymph nodes. Thyroid. 2004;14:959-963. [EL 3]
176. Snozek CL, Chambers EP, Reading CC, et al. Serum thyroglobulin, high-resolution ultrasound, and lymph node thyroglobulin in diagnosis of differentiated thyroid carcinoma nodal metastases. J Clin Endocrinol Metab. 2007;92:4278-4281. [EL 2]
177. Cunha N, Rodrigues F, Curado F, et al. Thyroglobulin detection in fine-needle aspirates of cervical lymph nodes: a technique for the diagnosis of metastatic differentiated thyroid cancer. Eur J Endocrinol. 2007;157:101-107. [EL 3]
178. Baloch ZW, Barroeta JE, Walsh J, et al. Utility of thyroglobulin measurement in fine-needle aspiration biopsy specimens of lymph nodes in the diagnosis of recurrent thyroid carcinoma. Cytojournal. 2008;5:1. [EL 2]
179. Kim MJ, Kim EK, Kim BM, et al. Thyroglobulin measurement in fine-needle aspirate washouts: the criteria for neck node dissection for patients with thyroid cancer. Clin Endocrinol (Oxf). 2009;70:145-151. [EL 3]
180. Torres MR, Nóbrega Neto SH, Rosas RJ, et al. Thyroglobulin in the washout fluid of lymph-node biopsy: what is its role in the follow-up of differentiated thyroid carcinoma? Thyroid. 2014;24:7-18. [EL 4]
181. Grani G, Fumarola A. Thyroglobulin in lymph node fine-needle aspiration washout: a systematic review and meta-analysis of diagnostic accuracy. J Clin Endocrinol Metab. 2014;99:1970-1982. [EL 2]
182. Lee YH, Seo HS, Suh SI, et al. Cut-off value for needle washout thyroglobulin in athyrotropic patients. Laryngoscope. 2010;120:1120-1124. [EL 3]
183. Bournaud C, Charrié A, Nozières C, et al. Thyroglobulin measurement in fine-needle aspirates of lymph nodes in patients with differentiated thyroid cancer: a simple definition of the threshold value, with emphasis on potential pitfalls of the method. Clin Chem Lab Med. 2010;48:1171-1177. [EL 3]
184. Giovanella L, Bongiovanni M, Trimboli P. Diagnostic value of thyroglobulin assay in cervical lymph node fine-needle aspirations for metastatic differentiated thyroid cancer. Curr Opin Oncol. 2013;25:6-13. [EL 4]
185. Jung JY, Shin JH, Han BK, Ko EY. Optimized cutoff value and indication for washout thyroglobulin level according to ultrasound findings in patients with well-differentiated thyroid cancer. AJNR Am J Neuroradiol. 2013;34:2349-2353. [EL 3]
186. Boi F, Baghino G, Atzeni F, Lai ML, Faa G, Mariotti S. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies. J Clin Endocrinol Metab. 2006;91:1364-1369. [EL 3]
187. Jeon MJ, Park JW, Han JM, et al. Serum antithyroglobulin antibodies interfere with thyroglobulin detection in fine-needle aspirates of metastatic neck nodes in papillary thyroid carcinoma. J Clin Endocrinol Metab. 2013;98: 153-160. [EL 2]
188. Boi F, Maurelli I, Pinna G, et al. Calcitonin measurement in wash-out fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab. 2007;92: 2115-2118. [EL 3]
189. Kudo T, Miyauchi A, Ito Y, Takamura Y, Amino N, Hirokawa M. Diagnosis of medullary thyroid carcinoma by calcitonin measurement in fine-needle aspiration biopsy specimens. Thyroid. 2007;17:635-638. [EL 3]
190. Abraham D, Gault PM, Hunt J, Bentz J. Calcitonin estimation in neck lymph node fine-needle aspirate fluid prevents misinterpretation of cytology in patients with metastatic medullary thyroid cancer. Thyroid. 2009;19: 1015-1016. [EL 3]
191. Trimboli P, Cremonini N, Ceriani L, et al. Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: a retrospective multicentre study. Clin Endocrinol (Oxf). 2014;80:135-140. [EL 2]
192. Marcocci C, Mazzeo S, Bruno-Bossio G, et al. Preoperative localization of suspicious parathyroid adenomas by assay of parathyroid hormone in needle aspirates. Eur J Endocrinol. 1998;139:72-77. [EL 3]
193. Kiblut NK, Cussac JF, Soudan B, et al. Fine needle aspiration and intraparathyroid intact parathyroid hormone measurement for reoperative parathyroid surgery. World J Surg. 2004;28:1143-1147. [EL 3]
194. Maser C, Donovan P, Santos F, et al. Sonographically guided fine needle aspiration with rapid parathyroid hormone assay. Ann Surg Oncol. 2006;13:1690-1695. [EL 2]
195. Erbil Y, Salmaslioglu A, Kabul E, et al. Use of preoperative parathyroid fine-needle aspiration and parathormone assay in the primary hyperparathyroidism with concomitant thyroid nodules. Am J Surg. 2007;193:665-671. [EL 3]
196. Owens CL, Rekhtman N, Sokoll L, Ali SZ. Parathyroid hormone assay in fine-needle aspirate is useful in differentiating inadvertently sampled parathyroid tissue from thyroid lesions. Diagn Cytopathol. 2008;36:227-231. [EL 3]
197. Kwak JY, Kim EK, Moon HJ, et al. Parathyroid incidentalomas detected on routine ultrasound-directed fine-needle aspiration biopsy in patients referred for thyroid nodules and the role of parathyroid hormone analysis in the samples. Thyroid. 2009;19:743-748. [EL 3]
198. Renshaw AA, Pinnar N. Comparison of thyroid fine-needle aspiration and core needle biopsy. Am J Clin Pathol. 2007;128:370-374. [EL 3]
199. Choi SH, Baek JH, Lee JH, et al. Thyroid nodules with initially non-diagnostic, fine-needle aspiration results: comparison of core-needle biopsy and repeated fine-needle aspiration. Eur Radiol. 2014;24:2819-2826. [EL 2]
200. Zhang S, Ivanovic M, Nemcek AA Jr, Defrias DV, Lucas E, Nayar R. Thin core needle biopsy crush preparations in conjunction with fine-needle aspiration for the evaluation of thyroid nodules: a complementary approach. Cancer. 2008;114:512-518. [EL 3]
201. Yoon RG, Baek JH, Lee JH, et al. Diagnosis of thyroid follicular neoplasm: fine-needle aspiration versus core-needle biopsy. Thyroid. 2014;24:1612-1617. [EL 2]
202. Nasrollah N, Trimboli P, Guidobaldi L, et al. Thin core biopsy should help to discriminate thyroid nodules cytologically classified as indeterminate: a new sampling technique. Endocrine. 2013;43:659-665. [EL 3]
203. Bartolazzi A, Orlandi F, Saggiorato E, et al. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol. 2008;9:543-549. [EL 2]
204. de Matos PS, Ferreira AP, de Oliveira Facuri F, Assumpcão LV, Metze K, Ward LS. Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy. Histopathology. 2005;47:391-401. [EL 2]
205. Saggiorato E, De Pompa R, Volante M, et al. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer. 2005;12:305-317. [EL 2]
206. Takano T, Miyauchi A, Matsuzuka F, Yoshida H, Kuma K, Amino N. Ubiquitous expression of galectin-3 mRNA in benign and malignant thyroid tumors. Cancer Lett. 2003;199:69-73. [EL 3]
207. Volante M, Bozzalla-Cassione F, DePompa R, et al. Galectin-3 and HBME-1 expression in oncocytic cell tumors of the thyroid. Virchows Arch. 2004;445:183-188. [EL 3]
208. Faggiano A, Caillou B, Lacroix L, et al. Functional characterization of human thyroid tissue with immunohistochemistry. Thyroid. 2007;17:203-211. [EL 4]
209. Freitas BC, Cerutti JM. Genetic markers differentiating follicular thyroid carcinoma from benign lesions. Mol Cell Endocrinol. 2010;321:77-85. [EL 4]
210. de Matos LL, Del Giglio AB, Matsubayashi CO, de Lima Farah M, Del Giglio A, da Silva Pinhal MA. Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis. Diagn Pathol. 2012;7:97. [EL 4]
211. Cibas ES, Baloch ZW, Fellegara G, et al. A prospective assessment defining the limitations of thyroid nodule pathologic evaluation. Ann Intern Med. 2013;159:325-332. [EL 2]
212. Nikiforov YE, Ohori NP, Hodak SP, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96:3390-3397. [EL 2]
213. Nikiforov YE, Steward DL, Robinson-Smith TM, et al. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. J Clin Endocrinol Metab. 2009;94:2092-2098. [EL 2]
214. Cantara S, Capezzone M, Marchisotta S, et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab. 2010;95:1365-1369. [EL 2]
215. Eszlinger M, Krogdahl A, Munz S, et al. Impact of molecular screening for point mutations and rearrangements in routine air-dried fine-needle aspiration samples of thyroid nodules. Thyroid. 2014;24:305-313. [EL 2]
216. Alexander EK, Kennedy GC, Baloch ZW, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367:705-715. [EL 2]
217. McIver B. Evaluation of the thyroid nodule. Oral Oncol. 2013;49:645-653. [EL 4]
218. Harrell RM, Bimston DN. Surgical utility of Afirma: effects of high cancer prevalence and oncocytic cell types in patients with indeterminate thyroid cytology. Endocr Pract. 2014;20:364-369. [EL 2]
219. Eszlinger M, Hegedüs L, Paschke R. Ruling in or ruling out thyroid malignancy by molecular diagnostics of thyroid nodules. Best Pract Res Clin Endocrinol Metab. 2014;28:545-557. [EL 4]
220. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159:676-690. [EL 3]
221. Melo M, da Rocha AG, Vinagre J, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014;99:E754-E765. [EL 2]
222. Liu R, Xing M. Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. Endocr Relat Cancer. 2014;21:825-830. [EL 2]
223. Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyrotropin (TSH) assays. Clin Chem. 1996;42:140-145. [EL 4-review]
224. Völzke H, Alte D, Kohlmann T, et al. Reference intervals of serum thyroid function tests in a previously iodine-deficient area. Thyroid. 2005;15:279-285. [EL 2]
225. Völzke H, Schmidt Co, John U, et al. Reference levels for serum thyroid function tests of diagnostic and prognostic significance. Horm Metab Res. 2010;42:809-814. [EL 2]
226. Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid. 2003;13:3-126. [EL 4-guidelines]
227. Ross DS. Laboratory assessment of thyroid function [Internet]. UpToDate: Cooper DS, Mulder JE, eds. 2015 [last updated 2014 Dec 19]. Available at: http://www.uptodate.com/contents/laboratory-assessment-of-thyroid-function. Accessed on April 29, 2015. [EL 4-review]
228. Hegedüs L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev. 2003;24:102-32. [EL 4-review]
229. Carle A, Pedersen IB, Knudsen N, et al. Thyroid volume in hypothyroidism due to autoimmune disease follows a unimodal distribution: evidence against primary thyroid atrophy and autoimmune thyroiditis being distinct diseases. J Clin Endocrinol Metab. 2009;94:833-839. [EL 3]
230. Wallaschofski H, Orda C, Georgi P, Miehle K, Paschke R. Distinction between autoimmune and non-autoimmune hyperthyroidism by determination of TSH-receptor antibodies in patients with the initial diagnosis of toxic multinodular goiter. Horm Metab Res. 2001;33:504-507. [EL 3]
231. Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays. Clin Endocrinol (Oxf). 2001;55:381-390. [EL 3]
232. Date J, Feldt-Rasmussen U, Blichert-Toft M, Hegedüs L, Graversen HP. Long-term observation of serum thyroglobulin after resection of nontoxic goiter and relation to ultrasonographically demonstrated relapse. World J Surg. 1996;20:351-356; discussion 357. [EL 3]
233. Giovanella L, Ceriani L, Ghelfo A, Maffioli M, Keller F. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy. Clin Endocrinol (Oxf). 2007;67:547-551. [EL 3]
234. Cohen R, Campos JM, Salaün C, et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC). J Clin Endocrinol Metab. 2000;85:919-922. [EL 3]
235. Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. J Clin Endocrinol Metab. 2004;89:163-168. [EL 3]
236. Brandi ML, Gagel RF, Angeli A, et al. Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab. 2001;86:5658-5671. [EL 4-guidelines]
237. Costante G, Meringolo D, Durante C, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007;92:450-455. [EL 2]
238. Cheung K, Roman SA, Wang TS, Walker HD, Sosa JA. Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. J Clin Endocrinol Metab. 2008;93:2173-2180. [EL 3]
239. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:109-142. [EL 4-guidelines]
240. Machens A, Hoffmann F, Sekulla C, Dralle H. Importance of gender-specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer. Endocr Relat Cancer. 2009;16:1291-1298. [EL 3]
241. d'Herbomez M, Caron P, Bauters C, et al. Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking. Eur J Endocrinol. 2007;157:749-755. [EL 3]
242. Karges W, Dralle H, Raue F, et al. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes. 2004;112:52-58. [EL 3]
243. Rink T, Truong PN, Schroth HJ, Diener J, Zimny M, Grünwald F. Calculation and validation of a plasma calcitonin limit for early detection of medullary thyroid carcinoma in nodular thyroid disease. Thyroid. 2009;19:327-332. [EL 3]
244. Mian C, Perrino M, Colombo C, et al. Refining calcium test for the diagnosis of medullary thyroid cancer: cutoffs, procedures, and safety. J Clin Endocrinol Metab. 2014;99:1656-1664. [EL 3]
245. Doyle P, Duren C, Nerlich K, et al. Potency and tolerance of calcitonin stimulation with high-dose calcium versus pentagastrin in normal adults. J Clin Endocrinol Metab. 2009;94:2970-2974. Erratum in: J Clin Endocrinol Metab. 2009;94:4629. [EL 2]
246. Russo M, Scollo C, Padova G, Vigneri R, Pellegriti G. Cardiac arrest after intravenous calcium administration for calcitonin stimulation test. Thyroid. 2014;24:606-607. [EL 4].
247. Colombo C, Verga U, Mian C, et al. Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. J Clin Endocrinol Metab. 2012;97:905-913. [EL 3]
248. Wohllk N, Cote GJ, Bugalho MM, et al. Relevance of RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab. 1996;81:3740-3745. [EL 3]
249. Elisei R, Alevizaki M, Conte-Devolx B, Frank-Raue K, Leite V, Williams GR. 2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer. Eur Thyroid J. 2013;1:216-231. [EL 4]
250. McHenry CR, Slusarczyk SJ, Askari AT, et al. Refined use of scintigraphy in the evaluation of nodular thyroid disease. Surgery. 1998;124:656-661; discussion 661-662. [EL 3]
251. Meier DA, Kaplan MM. Radioiodine uptake and thyroid scintiscanning. Endocrinol Metab Clin North Am. 2001;30:291-313, viii. [EL 4-review]
252. Bonnema SJ, Bennedbaek FN, Hegedüs L. Danish endocrinologists' examination and treatment of non-toxic multinodular goiter: a questionnaire study [in Danish]. Ugeskr Laeger. 2001;163:1265-1269. [EL 3]
253. Hillenhinrichs H, Emrich D. Euthyroid goiter with and without functional autonomy in the euthyroid phase: a comparison [in German]. Nuklearmedizin. 1998;37:95-100. [EL 3]
254. Tollin SR, Fallon EF, Mikhail M, Goldstein H, Yung E. The utility of thyroid nuclear imaging and other studies in the detection and treatment of underlying thyroid abnormalities in patients with endogenous subclinical thyrotoxicosis. Clin Nucl Med. 2000;25:341-347. [EL 3]
255. Krohn K, Wohlgemuth S, Gerber H, Paschke R. Hot microscopic areas of iodine-deficient euthyroid goitres contain constitutively activating TSH receptor mutations. J Pathol. 2000;192:37-42. [EL 3]
256. Pacella CM, Mauri G, Achille, G et al. Outcomes and risk factors for complications of laser ablation for thyroid nodules. A multicenter study on 1531 patients. J Clin Endocrinol Metab. 2015;100:3903-3910. [EL 3]
257. Choi YS, Hong SW, Kwak JY, Moon HJ, Kim EK. Clinical and ultrasonographic findings affecting nondiagnostic results upon the second fine needle aspiration for thyroid nodules. Ann Surg Oncol. 2012;19:2304-2309. [EL 3]
258. Singh RS, Wang HH. Timing of repeat thyroid fine-needle aspiration in the management of thyroid nodules. Acta Cytol. 2011;55:544-548. [EL 3]
259. Baloch ZW, LiVolsi VA. Post fine-needle aspiration histologic alterations of thyroid revisited. Am J Clin Pathol. 1999;112:311-316. [EL 4]
260. Na DG, Kim JH, Sung JY, et al. Core-needle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined significance by the Bethesda system for reporting thyroid cytopathology. Thyroid. 2012;22:468-475. [EL 3]
261. van Roosmalen J, van Hemel B, Suurmeijer A, et al. Diagnostic value and cost considerations of routine fine-needle aspirations in the follow-up of thyroid nodules with benign readings. Thyroid. 2010;20:1359-1365. [EL 2]
262. Porterfield JR Jr, Grant CS, Dean DS, et al. Reliability of benign fine needle aspiration cytology of large thyroid nodules. Surgery. 2008;144:963-968; discussion 968-969. [EL 3]
263. Yoon JH, Kwak JY, Moon HJ, Kim MJ, Kim EK. The diagnostic accuracy of ultrasound-guided fine-needle aspiration biopsy and the sonographic differences between benign and malignant thyroid nodules 3 cm or larger. Thyroid. 2011;21:993-1000. [EL 2]
264. Gharib H, James EM, Charboneau JW, Naessens JM, Offord KP, Gorman CA. Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study. N Engl J Med. 1987;317:70-75. [EL 1]
265. La Rosa GL, Ippolito AM, Lupo L, et al. Cold thyroid nodule reduction with L-thyroxine can be predicted by initial nodule volume and cytological characteristics. J Clin Endocrinol Metab. 1996;81:4385-4387. [EL 2]
266. Grussendorf M, Reiners C, Paschke R, Wegscheider K; LISA Investigators. Reduction of thyroid nodule volume by levothyroxine and iodine alone and in combination: a randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2011;96:2786-2795. [EL 1]
267. Wémeau JL, Caron P, Schvartz C, et al. Effects of thyroid-stimulating hormone suppression with levothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable changes: a randomized, double-blind, placebo-controlled trial by the French Thyroid Research Group. J Clin Endocrinol Metab. 2002;87: 4928-4934. [EL 1]
268. Hegedüs L, Nygaard B, Hansen JM. Is routine thyroxine treatment to hinder postoperative recurrence of nontoxic goiter justified? J Clin Endocrinol Metab. 1999;84:756-760. [EL 2]
269. Moalem J, Suh I, Duh QY. Treatment and prevention of recurrence of multinodular goiter: an evidence-based review of the literature. World J Surg. 2008;32:1301-1312. [EL 4]
270. Fogelfeld L, Wiviott MB, Shore-Freedman E, et al. Recurrence of thyroid nodules after surgical removal in patients irradiated in childhood for benign conditions. N Engl J Med. 1989;30:320:835-840. [EL 3]
271. Faber J, Galloe AM. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Eur J Endocrinol. 1994;130:350-356. [EL 1]
272. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab. 1996;81:4278-4289. [EL 1]
273. Abrahamsen B, Jorgensen HL, Laulund AS, Nybo M, Brix TH, Hegedüs L. Low serum thyrotropin level and duration of suppression as a predictor of major osteoporotic fractures: the OPENTHYRO register cohort. J Bone Miner Res. 2014;29:2040-2050. [EL 2]
274. Selmer C, Olesen JB, Hansen ML, et al. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. BMJ. 2012;345:e7895. [EL 2]
275. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet. 2001;358:861-865. [EL 2]
276. Brandt F, Almind D, Christensen K, Green A, Brix TH, Hegedüs L. Excess mortality in hyperthyroidism: the influence of preexisting comorbidity and genetic confounding: a Danish nationwide register-based cohort study of twins and singletons. J Clin Endocrinol Metab. 2012;97:4123-4129. [EL 2]
277. Laulund AS, Nybo M, Brix TH, Abrahamsen B, Jorgensen HL, Hegedüs L. Duration of thyroid dysfunction correlates with all-cause mortality: the OPENTHYRO Register Cohort. PLoS One. 2014;9:e110437. [EL 2]
278. Fast S, Bonnema SJ, Hegedüs L. The majority of Danish nontoxic goiter patients are ineligible for Levothyroxine suppressive therapy. Clin Endocrinol (Oxf). 2008;69:653-658. [EL 3]
279. Fiore E, Rago T, Provenzale MA, et al. L-thyroxine-treated patients with nodular goiter have lower serum TSH and lower frequency of papillary thyroid cancer: results of a cross-sectional study on 27,914 patients. Endocr Relat Cancer. 2010;17:231-239. [EL 3]
280. Dralle H, Machens A, Thanh PN. Minimally invasive compared with conventional thyroidectomy for nodular goitre. Best Pract Res Clin Endocrinol Metab. 2014;28: 589-599. [EL 4]
281. Miccoli P, Minuto MN, Ugolini C, Pisano R, Fosso A, Berti P. Minimally invasive video-assisted thyroidectomy for benign thyroid disease: an evidence-based review. World J Surg. 2008;32:1333-1340. [EL 4-review]
282. Lombardi CP, Raffaelli M, Princi P, De Crea C, Bellantone R. Minimally invasive video-assisted functional lateral neck dissection for metastatic papillary thyroid carcinoma. Am J Surg. 2007 Jan;193(1):114-8. [EL 4]
283. Papini E, Pacella CM, Misischi I, et al. The advent of ultrasound-guided ablation techniques in nodular thyroid disease: towards a patient-tailored approach. Best Pract Res Clin Endocrinol Metab. 2014;28:601-618. [EL 4]
284. Gharib H, Hegedüs L, Pacella CM, Baek JH, Papini E. Clinical review: nonsurgical, image-guided, minimally invasive therapy for thyroid nodules. J Clin Endocrinol Metab. 2013;98:3949-3957. [EL 4]
285. Verde G, Papini E, Pacella CM, et al. Ultrasound guided percutaneous ethanol injection in the treatment of cystic thyroid nodules. Clin Endocrinol (Oxf). 1994;41:719-724. [EL 1]
286. Zingrillo M, Torlontano M, Chiarella R, et al. Percutaneous ethanol injection may be a definitive treatment for symptomatic thyroid cystic nodules not treatable by surgery: five-year follow-up study. Thyroid. 1999;9:763-767. [EL 3]
287. Bennedbaek FN, Hegedüs L. Treatment of recurrent thyroid cysts with ethanol: a randomized double-blind controlled trial. J Clin Endocrinol Metab. 2003;88:5773-5777. [EL 1]
288. Lippi F, Ferrari C, Manetti L, et al. Treatment of solitary autonomous thyroid nodules by percutaneous ethanol injection: results of an Italian multicenter study. The Multicenter Study Group. J Clin Endocrinol Metab. 1996; 81:3261-3264. [EL 3]
289. Zingrillo M, Collura D, Ghiggi MR, Nirchio V, Trischitta V. Treatment of large cold benign thyroid nodules not eligible for surgery with percutaneous ethanol injection. J Clin Endocrinol Metab. 1998;83:3905-3907. [EL 3]
290. Bennedbaek FN, Nielsen LK, Hegedüs L. Effect of percutaneous ethanol injection therapy versus suppressive doses of L-thyroxine on benign solitary solid cold thyroid nodules: a randomized trial. J Clin Endocrinol Metab. 1998;83:830-835. [EL 1]
291. Pacella CM, Bizzarri G, Guglielmi R, et al. Thyroid tissue: US-guided percutaneous interstitial laser ablationa feasibility study. Radiology. 2000;217:673-677. [EL 3]
292. Dossing H, Bennedbaek FN, Hegedüs L. Effect of ultrasound-guided interstitial laser photocoagulation on benign solitary solid cold thyroid nodulesa randomised study. Eur J Endocrinol. 2005;152:341-345. [EL 2]
293. Dossing H, Bennedbaek FN, Hegedüs L. Effect of ultrasound-guided interstitial laser photocoagulation on benign solitary solid cold thyroid nodules: one versus three treatments. Thyroid. 2006;16:763-768. [EL 3]
294. Papini E, Rago T, Gambelunghe G, et al. Long-term efficacy of ultrasound-guided laser ablation for benign solid thyroid nodules: results of a three-year multicenter prospective randomized trial. J Clin Endocrinol Metab. 2014;99:3653-3659. [EL 1]
295. Papini E, Guglielmi R, Bizzarri G, et al. Treatment of benign cold thyroid nodules: a randomized clinical trial of percutaneous laser ablation versus levothyroxine therapy or follow-up. Thyroid. 2007;17:229-235. [EL 1]
296. Dossing H, Bennedbæk FN, Hegedüs L. Long-term outcome following interstitial laser photocoagulation of benign cold thyroid nodules. Eur J Endocrinol. 2011;165: 123-128. [EL 2]
297. Baek JH, Lee JH, Valcavi R, Pacella CM, Rhim H, Na DG. Thermal ablation for benign thyroid nodules: radiofrequency and laser. Korean J Radiol. 2011;12:525-540. [EL 4]
298. Deandrea M, Limone P, Basso E, et al. US-guided percutaneous radiofrequency thermal ablation for the treatment of solid benign hyperfunctioning or compressive thyroid nodules. Ultrasound Med Biol. 2008;34:784-791. [EL 3]
299. Spiezia S, Garberoglio R, Milone F, et al. Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation. Thyroid. 2009;19: 219-225. [EL 2]
300. Baek JH, Moon WJ, Kim YS, Lee JH, Lee D. Radiofrequency ablation for the treatment of autonomously functioning thyroid nodules. World J Surg. 2009; 33:1971-1977. [EL 3]
301. Fuller CW, Nguyen SA, Lohia S, Gillespie MB. Radiofrequency ablation for treatment of benign thyroid nodules: systematic review. Laryngoscope. 2014;124:346-353. [EL 1]
302. Ha EJ, Baek JH, Kim KW, et al. Comparative efficacy of radiofrequency and laser ablation for the treatment of benign thyroid nodules: systematic review including traditional pooling and bayesian network meta-analysis. J Clin Endocrinol Metab. 2015;100:1903-1911. [EL 1]
303. Pacella CM, Mauri G, Achille G, et al. Outcomes and Risk Factors for Complications of Laser Ablation for Thyroid Nodules. A Multicenter Study on 1531 Patients. J Clin Endocrinol Metab. 2015;100:3903-3910. [EL 3]
304. Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012;33:920-980. [EL 4]
305. Meier DA, Brill DR, Becker DV, et al. Procedure guideline for therapy of thyroid disease with (131)iodine. J Nucl Med. 2002;43:856-861. [EL 4-guidelines]
306. Nygaard B, Hegedüs L, Nielsen KG, Ulriksen P, Hansen JM. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clin Endocrinol (Oxf). 1999;50:197-202. [EL 3]
307. Dietlein M, Dressler J, Grunwald F, et al. Guideline for radioiodine therapy for benign thyroid diseases (version 4) [in German]. Nuklearmedizin. 2007;46:220-223. [EL 4-guidelines]
308. Reiners C, Schneider P. Radioiodine therapy of thyroid autonomy. Eur J Nucl Med Mol Imaging. 2002;29 Suppl 2:S471-S478. [EL 3]
309. Nygaard B, Hegedüs L, Ulriksen P, Nielsen KG, Hansen JM. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med. 1999;159:1364-1368. [EL 2]
310. Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab. 2007;92:2190-2196. Erratum in: J Clin Endocrinol Metab. 2007;92:4008. [EL 2]
311. Ron E, Doody MM, Becker DV, et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA. 1998;280:347-355. [EL 3]
312. Brandt F, Thvilum M, Almind D, et al. Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study. PLoS One. 2013;8:e66711. [EL 2]
313. Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study. Clin Endocrinol (Oxf). 2005;62:331-335. [EL 3]
314. Nygaard B, Faber J, Veje A, Hegedüs L, Hansen JM. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy. Thyroid. 1999;9:477-481. [EL 3]
315. Nygaard B, Knudsen JH, Hegedüs L, Scient AV, Hansen JE. Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter. J Clin Endocrinol Metab. 1997;82:2926-2930. [EL 3]
316. Wallaschofski H, Muller D, Georgi P, Paschke R. Induction of TSH-receptor antibodies in patients with toxic multinodular goitre by radioiodine treatment. Horm Metab Res. 2002;34:36-39. [EL 3]
317. Bonnema SJ, Bennedbaek FN, Veje A, Marving J, Hegedüs L. Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab. 2004;89:4439-4444. [EL 2]
318. Walter MA, Briel M, Christ-Crain M, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ. 2007;334:514. [EL 1]
319. Namwongprom S, Unachak K, Dejkhamron P, Ua-apisitwong S, Ekmahachai M. Radioactive iodine for thyrotoxicosis in childhood and adolescence: treatment and outcomes. J Clin Res Pediatr Endocrinol. 2013; 5:95-97. [EL 2]
320. Hegedüs L, Hansen BM, Knudsen N, Hansen JM. Reduction of size of thyroid with radioactive iodine in multinodular non-toxic goitre. BMJ. 1988;297:661-662. [EL 3]
321. Bonnema SJ, Fast S, Hegedüs L. The role of radioiodine therapy in benign nodular goitre. Best Pract Res Clin Endocrinol Metab. 2014;28:619-631. [EL 4]
322. Nygaard B, Hegedüs L, Gervil M, Hjalgrim H, Søe-Jensen P, Hansen JM. Radioiodine treatment of multinodular non-toxic goitre. BMJ. 1993;307:828-832. [EL 3]
323. Wesche MF, Tiel-V Buul MM, Lips P, Smits NJ, Wiersinga WM. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metab. 2001;86:998-1005. [EL 1]
324. Weetman AP. Radioiodine treatment for benign thyroid diseases. Clin Endocrinol (Oxf). 2007;66:757-764. [EL 4-review]
325. Bonnema SJ, Bertelsen H, Mortensen J, et al. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab. 1999;84:3636-3641. [EL 4]
326. Huysmans DA, Hermus AR, Corstens FH, Barentsz JO, Kloppenborg PW. Large, compressive goiters treated with radioiodine. Ann Intern Med. 1994;121:757-762. [EL 3]
327. Jarlov AE, Hegedüs L, Kristensen LO, Nygaard B, Hansen JM. Is calculation of the dose in radioiodine therapy of hyperthyroidism worthwhile? Clin Endocrinol (Oxf). 1995;43:325-329. [EL 3]
328. Sørensen JR, Hegedüs L, Kruse-Andersen S, Godballe C, Bonnema SJ. The impact of goitre and its treatment on the trachea, airflow, oesophagus and swallowing function: a systematic review. Best Pract Res Clin Endocrinol Metab. 2014;28:481-494. [EL 2]
329. Watt T, Cramon P, Hegedüs L, et al. The thyroid-related quality of life measure ThyPRO has good responsiveness and ability to detect relevant treatment effects. J Clin Endocrinol Metab. 2014;99:3708-3717. [EL 2]
330. Cramon P, Bonnema SJ, Bjorner JB, et al. Quality of life in patients with benign nontoxic goiter: impact of disease and treatment response, and comparison with the general population. Thyroid. 2015;25:284-291. [EL 2]
331. Watt T, Cramon P, Frendl DM, Ware JE Jr; ThyQoL Group. Assessing health-related quality of life in patients with benign non-toxic goitre. Best Pract Res Clin Endocrinol Metab. 2014;28:559-575. [EL 4]
332. Fast S, Nielsen VE, Grupe P, et al. Prestimulation with recombinant human thyrotropin (rhTSH) improves the long-term outcome of radioiodine therapy for multinodular nontoxic goiter. J Clin Endocrinol Metab. 2012;97: 2653-2660. [EL 1]
333. Fast S, Nielsen VE, Bonnema SJ, Hegedüs L. Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapy. Eur J Endocrinol. 2009;160: 517-528. [EL 4-review]
334. Nielsen VE, Bonnema SJ, Boel-Jørgensen H, Grupe P, Hegedüs L. Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. Arch Intern Med. 2006;166:1476-1482. [EL 1]
335. Silva MN, Rubio IG, Romao R, et al. Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goitres. Clin Endocrinol (Oxf). 2004;60:300-308. [EL 3]
336. Barca MF, Gruppi C, Oliveira MT, et al. Cardiovascular assessment of hyperthyroid patients with multinodular goiter before and after radioiodine treatment preceded by stimulation with recombinant human TSH. Endocrine. 2007;32:175-181. [EL 3]
337. Nielsen VE, Bonnema SJ, Hegedüs L. Transient goiter enlargement after administration of 0.3 mg of recombinant human thyrotropin in patients with benign nontoxic nodular goiter: a randomized, double-blind, crossover trial. J Clin Endocrinol Metab. 2006;91:1317-1322. [EL 1]
338. Pena S, Arum S, Cross M, et al. 123I thyroid uptake and thyroid size at 24, 48, and 72 hours after the administration of recombinant human thyroid-stimulating hormone to normal volunteers. J Clin Endocrinol Metab. 2006;91: 506-510. [EL 3]
339. Fast S, Hegedüs L, Pacini F, et al. Long-term efficacy of modified-release recombinant human thyrotropin augmented radioiodine therapy for benign multinodular goiter: results from a multicenter, international, randomized, placebo-controlled, dose-selection study. Thyroid. 2014;24:727-735. [EL 1]
340. Fast S, Nielsen VE, Grupe P, Bonnema SJ, Hegedüs L. Optimizing 131I uptake after rhTSH stimulation in patients with nontoxic multinodular goiter: evidence from a prospective, randomized, double-blind study. J Nucl Med. 2009;50:732-737. [EL 1]
341. Graf H, Fast S, Pacini F, et al. Modified-release recombinant human TSH (MRrhTSH) augments the effect of (131)I therapy in benign multinodular goiter: results from a multicenter international, randomized, placebo-controlled study. J Clin Endocrinol Metab. 2011;96:1368-1376. [EL 1]
342. Rosario PW. Thyroid nodules with atypia or follicular lesions of undetermined significance (Bethesda Category III): importance of ultrasonography and cytological subcategory. Thyroid. 2014;24:1115-1120. [EL 2]
343. Baloch Z, LiVolsi VA, Jain P, et al. Role of repeat fine-needle aspiration biopsy (FNAB) in the management of thyroid nodules. Diagn Cytopathol. 2003;29:203-206. [EL 2]
344. Na DG, Kim JH, Sung JY, et al. Core-needle biopsy is more useful than repeat fine-needle aspiration in thyroid nodules read as nondiagnostic or atypia of undetermined significance by the Bethesda system for reporting thyroid cytopathology. Thyroid. 2012;22:468-475. [EL 2]
345. McIver B, Castro MR, Morris JC, et al. An independent study of a gene expression classifier (Afirma) in the evaluation of cytologically indeterminate thyroid nodules. J Clin Endocrinol Metab. 2014;99:4069-4077. [EL 2]
346. NCCN categories of evidence and consensus [Internet]. National Comprehensive Cancer Network: c2012. Available at: http://www.nccn.org/professionals/physician-gls/categories-of-consensus.asp. Accessed April 29, 2015. [EL 4-guidelines]
347. Haymart MR, Greenblatt DY, Elson DF, Chen H. The role of intraoperative frozen section if suspicious for papillary thyroid cancer. Thyroid. 2008;18:419-423. [EL 3]
348. Cobin RH, Gharib H, Bergman DA, et al. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract. 2001;7:202-220. Erratum in: Endocr Pract. 2008 Sep;14(6):802-803. Multiple author names added. [EL 4-guidelines]
349. Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787-803. Erratum in: Eur J Endocrinol. 2006;155:385. [EL 4-consensus]
350. Abalovich M, Amino N, Barbour LA, et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2007;92 8 Suppl:S1-47. [EL 4-guidelines]
351. Baloch ZW, Barroeta JE, Walsh J, et al. Utility of thyroglobulin measurement in fine-needle aspiration biopsy specimens of lymph nodes in the diagnosis of recurrent thyroid carcinoma. Cytojournal. 2008;5:1. [EL 4]
352. Ito Y, Miyauchi A. Nonoperative management of low-risk differentiated thyroid carcinoma. Curr Opin Oncol. 2015;27:15-20. [EL 4-review]
353. Freudenberg LS, Antoch G, Jentzen W, et al. Value of (124)I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol. 2004;14:2092-1098. [EL 3]
354. Papini E, Negro R, Pinchera A, et al. Thyroid nodule and differentiated thyroid cancer management in pregnancy. An Italian Association of Clinical Endocrinologists (AME) and Italian Thyroid Association (AIT) Joint Statement for Clinical Practice. J Endocrinol Invest. 2010;33:579-586. [EL 4]
355. Kung AW, Chau MT, Lao TT, Tam SC, Low LC. The effect of pregnancy on thyroid nodule formation. J Clin Endocrinol Metab. 2002;87:1010-1014. [EL 2]
356. Rosen IB, Korman M, Walfish PG. Thyroid nodular disease in pregnancy: current diagnosis and management. Clin Obstet Gynecol. 1997;40:81-89. [EL 4]
357. Marley EF, Oertel YC. Fine-needle aspiration of thyroid lesions in 57 pregnant and postpartum women. Diagn Cytopathol. 1997;16:122-125. [EL 3]
358. Moosa M, Mazzaferri EL. Outcome of differentiated thyroid cancer diagnosed in pregnant women. J Clin Endocrinol Metab. 1997;82:2862-2866. [EL 3]
359. Messuti I, Corvisieri S, Bardesono F, et al. Impact of pregnancy on prognosis of differentiated thyroid cancer: clinical and molecular features. Eur J Endocrinol. 2014; 170:659-666. [EL 2]
360. Galofré JC, Riesco-Eizaguirre G, Alvarez-Escolá C; Grupo de Trabajo de Cáncer de Tiroides de la Sociedad Española de Endocrinologìa y Nutrición. Clinical guidelines for management of thyroid nodule and cancer during pregnancy. Endocrinol Nutr. 2014 Mar;61: 130-138. [EL 4]
361. Vannucchi G, Perrino M, Rossi S, et al. Clinical and molecular features of differentiated thyroid cancer diagnosed during pregnancy. Eur J Endocrinol. 2010;162:145-151. [EL 3]
362. Rallison ML, Dobyns BM, Keating FR Jr, Rall JE, Tyler FH. Thyroid nodularity in children. JAMA. 1975; 233:1069-1072. [EL 4]
363. Hung W. Nodular thyroid disease and thyroid carcinoma. Pediatr Ann. 1992;21:50-57. [EL 4-review]
364. Raab SS, Silverman JF, Elsheikh TM, Thomas PA, Wakely PE. Pediatric thyroid nodules: disease demographics and clinical management as determined by fine needle aspiration biopsy. Pediatrics. 1995;95:46-49. [EL 3]
365. Amrikachi M, Ponder TB, Wheeler TM, Smith D, Ramzy I. Thyroid fine-needle aspiration biopsy in children and adolescents: experience with 218 aspirates. Diagn Cytopathol. 2005;32:189-192. [EL 3]
366. Chang SH, Joo M, Kim H. Fine needle aspiration biopsy of thyroid nodules in children and adolescents. J Korean Med Sci. 2006;21:469-473. [EL 3]
367. Canadian Pediatric Thyroid Nodule (CaPTN) Study Group. The Canadian pediatric thyroid nodule study: an evaluation of current management practices. J Pediatr Surg. 2008;43:826-830. [EL 4]
368. Drozd VM, Lushchik ML, Polyanskaya ON, et al. The usual ultrasonographic features of thyroid cancer are less frequent in small tumors that develop after a long latent period after the Chernobyl radiation release accident. Thyroid. 2009;19:725-734. [EL 2]
369. Buryk MA, Simons JP, Picarsic J, et al. Can malignant thyroid nodules be distinguished from benign thyroid nodules in children and adolescents by clinical characteristics? A review of 89 pediatric patients with thyroid nodules. Thyroid. 2015;25:392-400. [EL 2]
370. Feinmesser R, Lubin E, Segal K, Noyek A. Carcinoma of the thyroid in childrena review. J Pediatr Endocrinol Metab. 1997;10:561-568. [EL 4-review]
371. Alessandri AJ, Goddard KJ, Blair GK, Fryer CJ, Schultz KR. Age is the major determinant of recurrence in pediatric differentiated thyroid carcinoma. Med Pediatr Oncol. 2000;35:41-46. [EL 3]
372. Niedziela M, Breborowicz D, Trejster E, Korman E. Hot nodules in children and adolescents in western Poland from 1996 to 2000: clinical analysis of 31 patients. J Pediatr Endocrinol Metab. 2002;15:823-830. [EL 3]
373. Haynes RB, Wilczynski N, McKibbon KA, Walker CJ, Sinclair JC. Developing optimal search strategies for detecting clinically sound studies in MEDLINE. J Am Med Inform Assoc. 1994;1:447-458. [EL 4]
374. Hunt DL, McKibbon KA. Locating and appraising systematic reviews. Ann Intern Med. 1997;126:532-538. [EL 4]
375. Mechanick JI, Bergman DA, Braithwaite SS, Palumbo PJ; American Association of Clinical Endocrinologists Ad Hoc Task Force for Standardized Production of Clinical Practice Guidelines. American Association of Clinical Endocrinologists protocol for standardized production of clinical practice guidelines. Endocr Pract. 2004;10:353-361. Erratum in: Endocr Pract. 2008;14:802-803. Mechanick, Jeffrey I [added]; Bergman, Donald A [added]; Braithwaite, Susan Shapiro [added]; Palumbo, Pasquale J [added]. [EL 4-guidelines]
376. Mechanick JI, Kushner RF, Sugerman HJ, et al. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery Medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Endocr Pract. 2008;14 Suppl 1:1-83. Erratum in: Endocr Pract. 2009;15:768. [EL 4]